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Abstract
Background: Cardiovascular disease is the leading nonmalignant cause of late deaths in childhood cancer survivors.
Cardiovascular disease and cardiac dysfunction can remain asymptomatic for many years, but eventually lead to progressive
disease with high morbidity and mortality. Early detection and intervention are therefore crucial to improve outcomes.
Objective: In our study, we aim to assess the prevalence of preclinical cardiac dysfunction in adult childhood cancer survivors
using conventional and speckle tracking echocardiography; determine the association between cardiac dysfunction and
treatment-related risk factors (anthracyclines, alkylating agents, steroids, cardiac radiation) and modifiable cardiovascular risk
factors (abdominal obesity, hypertension); investigate the development of cardiac dysfunction longitudinally in a defined cohort;
study the association between cardiac dysfunction and other health outcomes like pulmonary disease, endocrine disease, renal
disease, quality of life, fatigue, strength and endurance, and physical activity; and gain experience conducting a clinical study of
childhood cancer survivors that will be extended to a national, multicenter study of cardiac complications.
Methods: For this retrospective cohort study, we will invite ≥5-year childhood cancer survivors who were treated at the University
Children's Hospital Bern, Switzerland with any chemotherapy or cardiac radiation since 1976 and who are ≥18 years of age at
the time of the study for a cardiac assessment at the University Hospital Bern. This includes 544 childhood cancer survivors, of
whom about half were treated with anthracyclines and/or cardiac radiation and half with any other chemotherapy. The standardized
cardiac assessment includes a medical history focusing on signs of cardiovascular disease and its risk factors, a physical examination,
anthropometry, vital parameters, the 1-minute sit-to-stand test, and echocardiography including 2-dimensional speckle tracking.
Results: We will invite 544 eligible childhood cancer survivors (median age at the time of the study, 32.5 years; median length
of time since diagnosis, 25.0 years) for a cardiac assessment. Of these survivors, 300 (55%) are at high risk, and 244 (45%) are
at standard risk of cardiac dysfunction.
Conclusions: This study will determine the prevalence of preclinical cardiac dysfunction in Swiss childhood cancer survivors,
inform whether speckle tracking echocardiography is more sensitive to cardiac dysfunction than conventional echocardiography,
and give a detailed picture of risk factors for cardiac dysfunction. The results will help improve primary treatment and follow-up
care of children with cancer.
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Introduction
Survival of childhood cancer has improved, and the number of
childhood cancer survivors (CCS) has greatly increased during
recent decades [1,2]. Consequently, more survivors face
increased long-term morbidity and mortality due to chronic
health conditions such as cardiovascular disease, pulmonary
disease, and secondary neoplasms [3-5]. Among these,
cardiovascular disease is the leading nonmalignant cause of
death among CCS [3] with a cumulative incidence that increases
up to 30 years after cancer diagnosis [6]. Heart failure,
myocardial infarction, pericardial and valvular disease, and
arrhythmias are all associated with treatments used in childhood
cancer patients.
Studies from North America, Germany, and The Netherlands
have assessed survivors exposed to cardiotoxic cancer therapy,
in whom a prevalence of subclinical cardiac dysfunction ranging
from 6% to 27% was identified via conventional
echocardiography [7-10]. This suggests that many CCS have
impaired cardiac function that might progress to clinical heart
failure later in life. The North American study also found that
a further 32% of survivors with otherwise normal conventional
echocardiography showed evidence of cardiac dysfunction with
abnormal strain measurements by speckle tracking
echocardiography, a novel echocardiographic technique [7].
Additional studies have also suggested that speckle tracking
echocardiography might be more sensitive to preclinical cardiac
dysfunction than conventional echocardiography in CCS [11,12].
Most studies have assessed survivors exposed to anthracyclines
and cardiac radiation, which are the most important
treatment-related risk factors [13]. Yet, other treatments may
also increase the risk of cardiac dysfunction in CCS. Survivors
who were not exposed to anthracyclines or cardiac radiation
have demonstrated decreased left ventricular (LV) mass and
increased cardiac biomarkers compared to siblings [14].
The North American Childhood Cancer Survivor Study analyzed
self-reported data on cardiovascular risk factors in more than
10,000 adult CCS and showed that hypertension alone and in
combination with other modifiable cardiovascular risk factors
significantly increased the risk for heart failure, coronary artery
disease, valvular disease, and arrhythmia in adult CCS [15].
The likelihood that modifiable cardiovascular risk factors might
potentiate the increased risk of treatment-related cardiovascular
disease in CCS thus motivates this study of cardiac dysfunction
in adult CCS.
Methods
Study Objectives
The first and primary objective of this study is to assess the
prevalence of preclinical cardiac dysfunction in adult CCS using
2-dimensional (2D) and 3-dimensional (3D) conventional and
2D speckle tracking echocardiography. Second, we will
determine the association between cardiac dysfunction and the
risk related with treatment (anthracyclines, alkylating agents,
steroids, and cardiac radiation) as well as the modifiable
cardiovascular risk factors abdominal obesity and hypertension.
Our third objective is to investigate the development of cardiac
dysfunction longitudinally in a defined cohort. Fourth, we will
study the association between cardiac dysfunction and other
health outcomes like pulmonary, endocrine, and renal diseases;
quality of life; fatigue; strength and endurance; and physical
activity. Finally, pursuing these objectives will provide
experience conducting a clinical study of CCS that could be
used for a national, multicenter study of cardiac complications.
Primary Outcome
The primary outcomes of this study are abnormal 2D and 3D
LV ejection fraction (LVEF) measured using conventional
echocardiography and abnormal global longitudinal strain (GLS)
measured using 2D speckle tracking echocardiography (Textbox
1).
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Textbox 1. Components of cardiac assessment collected for childhood cancer survivors.
Conventional echocardiography
• Left ventricular (LV) systolic function
• 2-dimensional (2D) and 3-dimensional (3D) LV ejection fraction (LVEF)
• LV diastolic function
• Early diastolic LV filling velocity (E)
• Late diastolic LV filling velocity (A)
• Early to late LV filling velocity (E/A ratio)
• Mitral annular early diastolic velocity (e’) (septal and lateral)
• Peak mitral flow velocity (E/e’ ratio)
• Peak tricuspid regurgitation (TR) velocity
• Left atrial (LA) maximum volume index
• Right atrium (RA), right ventricle (RV), RV/RA ratio
• Valvular dysfunction, respiratory variation, size of the vena cava
2D speckle tracking echocardiography
• LV systolic function
• Global longitudinal strain (GLS)
• Global circumferential strain (GCS)
• Global radial strain (GRS)
Personal history
• Demographic and socioeconomic characteristics
• Clinical characteristics
• Cardiac symptoms
• History of cardiovascular disease
• Modifiable cardiovascular risk factors
• Chronic conditions
• Sleeping habits
• Medications
• Thoracic surgeries
• Family history of cardiovascular disease and risk factors
• Pictorial images for perception of weight status
• Qualitative questions
Anthropometry and blood pressure
• Weight and height
• Waist and hip circumference
• Blood pressure
Physical examination
• Auscultation of the heart and lungs
• Palpation of pulses
• Carotid
• Radial
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Tibial•
• Dorsal feet
• Signs of heart failure
• Jugular vein pressure
• Hepato-jugular reflux
• Edema of the lower extremities
• Size of the liver and spleen
• Documentation of thoracic scars
1-minute sit-to-stand test
Counselling of survivors and medical letter
Online questionnaires
Secondary Outcomes
Secondary outcomes are other conventional echocardiographic
parameters of abnormal LV diastolic function (early diastolic
LV filling velocity [E], late diastolic LV filling velocity [A],
early to late LV filling velocity [E/A ratio], mitral annular early
diastolic velocity [e’], peak mitral flow velocity [E/e’ ratio],
peak tricuspid regurgitation [TR] velocity, left atrial [LA]
maximum volume index), right atrium [RA], right ventricle
[RV], RV/RA ratio, valvular dysfunction, respiratory variation,
and size of the vena cava, and speckle tracking
echocardiography–derived parameters of abnormal LV systolic
function (global circumferential strain [GCS], global radial
strain [GRS]). Other secondary outcomes include impaired
quality of life and fatigue.
Intermediate Outcomes and Exposures
We also collect information about treatment with anthracyclines,
alkylating agents, steroids, and cardiac radiation; modifiable
cardiovascular risk factors (abdominal obesity and
hypertension); and other health outcomes including pulmonary,
endocrine, and renal diseases; strength and endurance; and
physical activity.
Study Design, Study Population, and Inclusion Criteria
This retrospective cohort study is part of routine clinical
follow-up care and a collaborative and interdisciplinary effort
of the Childhood Cancer Registry, Swiss Childhood Cancer
Survivor Study, and departments of Pediatric Hematology and
Oncology and Pediatric and Adult Cardiology at the University
Hospital Bern, Switzerland (Textbox 2, Figure 1). The study
includes all ≥5 year CCS diagnosed with childhood cancer
starting in 1976, treated at the University Children’s Hospital
Bern in Switzerland with any chemotherapy and/or cardiac
radiation, aged ≥18 years at the time of the study, and registered
in the Childhood Cancer Registry. The registry includes all
patients in Switzerland diagnosed at age 0-20 years with
leukemia, lymphoma, central nervous system tumors, malignant
solid tumors, or Langerhans cell histiocytosis [16]. We classify
cancer diagnoses according to the International Classification
of Childhood Cancer, third edition into 12 main groups [17]
and Langerhans cell histiocytosis. Recent estimates indicate
that the registry includes >95% of children diagnosed at <16
years since 1995 in Switzerland [18]. We exclude survivors
who were treated with surgery only and/or radiation other than
cardiac radiation because these survivors have a low risk of
developing cardiac dysfunction. Ethics approval of this study
was granted by the Ethics Committee of the Canton of Bern,
Switzerland (KEK-BE: 2017-01612), and the study is registered
at ClinicalTrials.gov (identifier: NCT03790943). Informed
consent, as documented with a signature, is obtained from each
survivor prior to participation in the study.
JMIR Res Protoc 2020 | vol. 9 | iss. 6 | e17724 | p. 4http://www.researchprotocols.org/2020/6/e17724/
(page number not for citation purposes)
Schindera et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Textbox 2. Teams and staff members involved in the workflow of the study of preclinical diagnosis of cardiac dysfunction.
Childhood Cancer Registry
• Administrative staff
Swiss Childhood Cancer Survivor Study
• PhD student
• Study nurse
• Master students
Pediatric Hematology and Oncology
• Head of pediatric hematology and oncology
Department of Cardiology
• Cardiologists specialized in echocardiography
• Cardiologist specialized in cardio-oncology
• Nurse practitioner specialized in cardio-oncology
• Administrative staff
Figure 1. Responsible teams in the study of preclinical diagnosis of cardiac dysfunction in childhood cancer survivors.
Study Logistics
Current addresses of eligible survivors are obtained from the
Childhood Cancer Registry and updated via the Swiss postal
service where necessary (Figure 1). We send an invitation letter
to survivors explaining why a cardiac assessment is useful, and
it also describes the planned examinations and visit location in
the Department of Cardiology at the University Hospital Bern.
Survivors are asked to return a response form indicating their
interest in participation in the study and the date and place of
previous cardiac assessment(s). Nonresponders receive up to
two reminders by mail before we try to contact them by phone.
The administrative personnel of the Department of Cardiology
schedules an appointment for a cardiac assessment via mail
with survivors who agree to participate. The study is part of the
routine follow-up care offered to CCS and is paid for by health
insurance. All patient contacts are documented in a
patient-tracking database.
Medical Data Extraction
We extract the following data on each survivor from the cancer
registry: cancer diagnose(s), relapse(s), age at cancer diagnosis,
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year of cancer diagnosis, and whether the person had
chemotherapy, radiation (if so, the location of radiation),
surgery, or hematopoietic stem cell transplantation (Figure 1).
We collect cumulative doses of anthracyclines, steroids, and
alkylating agents from medical records (Textbox 3). We record
patient weight, patient height, and the doses in each
chemotherapy cycle. We calculate the cumulative doses per unit
body surface area, expressed in milligrams or grams per square
meter (Textbox 3).
Cardiac radiation includes different radiation fields [19] and is
collected from medical records (Textbox 3). We use the
maximum documented dose of the field involving the heart and
add the dose of total body irradiation.
Textbox 3. Cumulative doses of chemotherapy and cardiac radiation extracted from medical records.
Cumulative doses of chemotherapy
• Anthracyclines with doxorubicin-equivalent doses (mg/m2) [19]
• Doxorubicin x 1.0
• Daunorubicin x 0.5
• Epirubicin x 0.67
• Idarubicin x 5.0
• Mitoxantrone x 4.0
• Alkylating agents with cyclophosphamide-equivalent doses (mg/m2) [20]
• Cyclophosphamide x 1.0
• Ifosfamide x 4.09
• Steroids with prednisone-equivalent doses (g/m2) [21]
• Prednisone x 1.0
• Dexamethasone x 6.67
Cumulative doses of cardiac radiation [19]
• Cardiac radiation (gray)
• Chest
• Abdomen
• Whole or thoracic spine
• Total body irradiation
Definition of High-Risk and Standard-Risk Groups
Patients with exposure to any cumulative dose of anthracyclines
and/or cardiac radiation (chest, abdomen, whole or thoracic
spine, total body irradiation) are placed in the high-risk group
(Figure 2). High-risk patients are assessed longitudinally with
baseline and follow-up cardiac assessments according to the
Children’s Oncology Group Long-Term Follow-Up Guidelines,
Version 5.0, October 2018 [19]. Survivors with exposure to any
chemotherapy other than anthracyclines are assigned to a
standard-risk group and evaluated cross-sectionally unless a
cardiac follow-up assessment is clinically indicated. All
survivors with surgery only or radiation other than cardiac are
excluded from this study and are seen only within the routine
follow-up care without echocardiography.
Figure 2. Study design and risk group stratification of childhood cancer survivors.
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Patient Information and Informed Consent
At the cardiac assessment, we give survivors oral and written
information about the clinical study (Figure 1). The general
hospital informed consent form that participants sign is a
standard consent form widely used in Swiss inpatient and
outpatient settings to enable research with clinical data.
Echocardiography and Definition of Cardiac
Dysfunction
Echocardiography is performed by experienced cardiologists
from the Department of Cardiology who are blinded with respect
to the patient’s cancer treatment and risk group (Textbox 2).
Conventional echocardiography includes assessment of LV
systolic function (2D and 3D LVEF), LV diastolic function (E,
A, E/A ratio, septal and lateral e’, E/e’ ratio, peak TR velocity,
LA maximum volume index), RA, RV, RV/RA ratio, valvular
dysfunction, respiratory variation, and size of the vena cava
(Textbox 1, Figure 1) using a GE Vivid E9 or E95 (GE
Vingmed, Horten, Norway). 2D speckle tracking
echocardiography includes GLS, GCS, and GRS and is
performed using vendor-independent software (Tomtec Imaging
Systems, Unterschleissheim, Germany).
We define cardiac dysfunction according to the American
Society of Echocardiography and European Association of
Cardiovascular Imaging recommendations [22,23].
LV systolic dysfunction is defined as 2D/3D LVEF <52% for
men and <54% for women [22].
The LV diastolic dysfunction definition depends on whether a
patient has normal or impaired LVEF [23]. In patients with
normal LVEF, four parameters and cutoff levels are used: (1)
E/e´ ratio >14, (2) septal e´ velocity <7 cm/s or lateral e´ velocity
<10 cm/s, (3) TR velocity >2.8 m/s, and (4) LA volume index
>34 mL/m². Diastolic function is defined as abnormal if more
than half of available parameters meet the cutoff levels, as
normal if more than half of available parameters do not meet
cutoff levels, and as inconclusive if half of the parameters do
not meet the cutoff levels. In patients with impaired LVEF, the
E/A ratio is used for stratification into three grades of diastolic
dysfunction. An E/A ratio ≤0.8 and a peak mitral flow velocity
E ≤50 cm/sec are defined as grade I diastolic dysfunction. An
E/A ratio ≥2.0 is defined as grade III diastolic dysfunction. If
the E/A ratio is ≤0.8 and peak mitral flow velocity E is >50
cm/sec, or E/A >0.8 but <2, three additional parameters and
cutoff values are used: (1) peak TR velocity >2.8 m/sec, (2)
E/e´ ratio >14, and (3) LA maximum volume index >34 mL/m².
Grade II diastolic dysfunction is present if more than half of
parameters meet the cutoff values, grade I diastolic dysfunction
is present if only one available parameter meets the cutoff levels,
and the study is inconclusive if only one parameter is available
or in case of 50% discordance [23].
Abnormal strain (GLS, GCS, GRS) is defined as >2 SD below
the mean using sex-specific, age-specific, vendor-specific, and
software-specific strain values [24].
Personal History
We take a comprehensive personal history of survivors'
demographic and socioeconomic characteristics: current
occupation, employment status, work hours per week, marital
status, offspring, and housing situation (Textbox 1, Figure 1).
We also obtain clinical characteristics including cardiac
symptoms (New York Heart Association class I-IV), history of
cardiovascular disease, modifiable cardiovascular risk factors
(hypertension, diabetes, dyslipidemia, smoking, physical
inactivity, drug consumption), chronic conditions (pulmonary,
endocrine, and renal diseases), sleeping habits, medications,
thoracic surgeries, and family history of cardiovascular diseases
and risk factors. To determine perception of weight status, we
use pictorial images of women and men similar to Harris et al
[25] and ask the patient to indicate the picture that best matches
the weight status of his or her parents, siblings, and the patient’s
own weight. We also ask patients: “Was it a big effort for you
to come to the hospital for today’s appointment, does your
history of childhood cancer play a role in your daily life, and
are you afraid that your treatment for cancer during childhood
caused any medical problems in adulthood?” We also ask
patients if they have any questions, requests, or wishes to direct
to us.
Anthropometry and Blood Pressure
Weight and standing height are measured using standard
procedures, while the patient is barefoot and in light clothes
(Textbox 1, Figure 1). Weight is determined to the nearest 0.1
kg and height to the nearest 0.5 cm. BMI is expressed as kg/m2
[26]. Waist and hip circumferences are measured using a
measuring tape to the nearest 0.1 cm. Waist circumference is
measured at the midpoint between the lower margin of the
lowest rib and the top of the iliac crest, and hip circumference
is measured at the widest circumference over the buttocks [26].
The waist-hip ratio is calculated as waist circumference divided
by hip circumference. Blood pressure is measured comfortably
in a quiet environment with three measurements repeated in a
sitting position, and the average of the last two readings is
recorded. Additional measurements are taken if the first two
readings of systolic or diastolic blood pressure differ by >10
mm Hg [27].
Physical Examination
We perform a thorough physical examination with special
emphasis on signs of cardiovascular disease (Textbox 1, Figure
1). This includes auscultation of the heart and lungs; palpation
of the carotid, radial, tibial, and dorsal foot artery pulses; and
examination of the jugular vein pressure, hepato-jugular reflux,
edema of the lower extremities, size of the liver and spleen, and
documentation of thoracic scars.
1-Minute Sit-to-Stand Test
We have the patient perform the 1-minute sit-to-stand test (STS),
which captures the number of times a person can stand up and
sit down on a regular chair in 1 minute (Textbox 1, Figure 1)
[28]. The STS is an estimate of lower body muscular strength
and endurance. We compare our population with
population-based, age-adjusted, and sex-adjusted Swiss
reference values [28].
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Counselling of Survivors and the Medical Letter
At the end of the cardiac assessment, a cardiologist specialized
in cardio-oncology and who did not perform the
echocardiography explains the results of the echocardiography
to survivors and counsels them on their cardiac function and
the presence (or absence) of modifiable cardiovascular risk
factors (Textbox 1, Figure 1). Recommendations on follow-up
assessments are based on the Children’s Oncology Group
Long-Term Follow-Up Guidelines, Version 5.0, October 2018
[19]. A medical letter summing up the results of the cardiac
assessment is sent to the survivor’s general practitioner.
Online Questionnaire
We ask survivors to complete 4 questionnaires after returning
home. The Short Form 36 Health Survey assesses health-related
quality of life [29] and has been used before in CCS [30]. The
Seven-Day Physical Activity Recall questionnaire measures
moderate physical activity, vigorous physical activity, and sleep
during the last 7 days [31]. Fatigue is assessed using the
Checklist Individual Strength questionnaire, a validated 20-item
questionnaire that identifies different aspects of fatigue within
the previous 2 weeks [32]. Diet and alcohol consumption are
obtained using questions from the Swiss Childhood Cancer
Survivor Study questionnaire [33]. We ask survivors to provide
separate informed consent for the online questionnaires.
Survivors not completing the online questionnaires within 2
weeks after the clinical visit are reminded by email.
Documentation
All parts of the cardiac assessment are directly entered into a
dedicated REDCap (version 8.5.19, Vanderbilt University,
Nashville, TN) database to minimize risk of disclosure. Within
the database, each survivor has a unique ID. No personal
information can be obtained with this number. Data containing
survivors’unique IDs are stored on encrypted devices or secured
servers at the University of Bern.
Cardiac Assessment, Phase 1
In 2016-2017, we started using standardized echocardiography
for cardiac assessment, as already described (Figure 3). At that
time, personal history, blood pressure, physical examination,
and the STS were not yet assessed in a standardized way. The
personal history and online questionnaires were retrospectively
completed by phone interviews between May 2017 and June
2017.
Figure 3. Recruitment of childhood cancer survivors eligible for the study, current as of October 1, 2019.
Cardiac Assessment, Phase 2
Since March 2018, we have been collecting all data in a
standardized way. Data collection is performed by the study
team from the Childhood Cancer Registry, Swiss Childhood
Cancer Survivor Study, Department of Pediatric Hematology
and Oncology at the University Hospital Bern, and Department
of Cardiology at the University Hospital Bern (Textbox 2, Figure
3).
Statistical Analyses and Power Calculations
We will compare characteristics of responders and
nonresponders using chi-square tests and perform univariable
and multivariable logistic regression analyses to investigate the
association between cardiotoxic treatment exposures
(anthracyclines, alkylating agents, steroids, cardiac radiation)
and modifiable cardiovascular risk factors (abdominal obesity,
hypertension) and cardiac dysfunction adjusting for sex, age at
study, and follow-up time.
From our eligible study population of 544 CSS and based on
an expected response rate of 65%, we estimate that
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approximately 354 survivors will attend the cardiac assessment
(Figure 3). Among these participants, about 55% (195/354) are
at high risk, and 45% (159/354) are at standard risk for cardiac
dysfunction. These numbers will provide a power of 80% and
α of .05 to detect a significant difference in cardiac dysfunction
in high-risk survivors, assuming 6% cardiac dysfunction for
LVEF and 32% for GLS [7]. In standard-risk survivors, the
prevalences of abnormal LVEF and GLS will be lower;
therefore, the sample size might be borderline sufficient.
Considering that we plan to extend this single-center cohort
study to a multicenter study, numbers will substantially increase.
We will use STATA software (Version 15.1, Stata Corporation,
Austin, TX) for statistical analyses.
Results
On January 1, 2018, the Childhood Cancer Registry included
711 survivors aged ≥18 years who had been diagnosed and
treated at the University Children’s Hospital Bern since 1976
and had survived ≥5 years (Figure 3). Among those, 103 were
excluded because of surgery as the only treatment, 35 survivors
because of radiation only other than cardiac, and 29 survivors
because they did not want to be contacted, had specific problems
(eg, did not want to be invited for clinical studies because of
emotional stress), or had died. Among the remaining survivors,
544 met the inclusion criteria for an invitation to a clinical visit
(Table 1, Figure 3). This number includes 300 survivors
(300/544, 55%) at high risk for cardiac dysfunction and 244
survivors (244/544, 45%) at standard risk for cardiac
dysfunction, with a median age at the time of the study of 32.5
years and a median time since diagnosis of 25.0 years (Table
1). In Phase 1 (2016-2017), 75 survivors were invited, and 49
survivors attended the cardiac assessment, for a response rate
of 65%; phase 2 is ongoing (Figure 3). We plan to recruit new
5-year survivors continuously into the study, so the size of the
cohort will increase and numbers will change.
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Table 1. Demographic and clinical characteristics of survivors eligible for participation in the cohort study (n=544), as of January 1, 2018.
n (%)Demographic and clinical characteristics
297 (55)Male sex
32.5 (25.4-38.5, 18.3-56.0)Age at the time of the study (years)a
Age category at the time of the study (years)
30 (6)<20
197 (36)20-29
207 (38)30-39
110 (20)>39
6.7 (3.1-12.5, 0.1-17.5)Age at diagnosis (years)a
Age category at diagnosis (years)
207 (38)<5
134 (25)5-9
149 (27)10-14
54 (10)15-19
25.0 (17.9-32.0, 6.2-42.0)Time since diagnosis (years)a
Time since diagnosis (years)
31 (6)5-10
130 (24)11-20
220 (40)21-30
147 (27)31-40
16 (3)>40
ICCC-3b cancer diagnoses
218 (40)I Leukemia
118 (22)II Lymphoma
35 (6)III CNSc
17 (3)IV Neuroblastoma
11 (2)V Retinoblastoma
38 (7)VI Renal tumor
6 (1)VII Hepatic tumor
40 (7)VIII Bone tumor
33 (6)IX Soft tissue sarcoma
8 (2)X Germ cell tumor
20 (4)XI&XII Other rare tumorsd
Era of treatment
136 (25)1976-1985
199 (36)1986-1995
156 (29)1996-2005
53 (10)2006-2012
Risk group
300 (55)High-riske
244 (45)Standard-riskf
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n (%)Demographic and clinical characteristics
213 (39)Any radiation therapy
329 (61)Any surgery
531 (98)Any chemotherapy
28 (5)Hematopoietic stem cell transplantation
amedian (IQR, range).
bICCC-3, International Classification of Childhood Cancer third edition.
cCNS, central nervous system.
dincluding Langerhans cell histiocytosis, other malignant epithelial neoplasms, malignant melanomas, and other or unspecified malignant neoplasms.
eanthracyclines and/or cardiac radiation.
fany chemotherapy other than anthracyclines.
Discussion
This retrospective, single-center cohort study is investigating
the prevalence of cardiac dysfunction and its risk factors in adult
CCS and comparing conventional and speckle tracking
echocardiography.
Few studies are comparable to ours. A single-center study in
The Netherlands included 525 adult CCS who had been treated
during 1966-1997 with anthracyclines, high-dose
cyclophosphamide, high-dose ifosfamide, and/or cardiac
radiation [8]. Conventional echocardiography was performed
during 1996-2004 to measure LV shortening fraction, and
subclinical cardiac dysfunction was observed in 27% of
survivors during a median follow-up time of 15 years. Another
hospital-based, single-center study at St. Jude Children’s
Research Hospital in the United States assessed 1820 adult CCS
exposed to anthracyclines and/or cardiac radiation during a
median follow-up time of 23 years using conventional and
speckle tracking echocardiography [7]. One-third of survivors
with normal LVEF had abnormal longitudinal strain seen on
speckle tracking echocardiography. Risk factors for pathological
findings in conventional and speckle tracking echocardiography
were treatment with anthracyclines and cardiac radiation. The
modifiable cardiovascular risk factors of hypertension,
abdominal obesity, dyslipidemia, and high fasting glucose were
associated with abnormal longitudinal strain but not with LVEF,
suggesting that speckle tracking might be more sensitive for
detecting cardiac dysfunction.
Conventional and speckle tracking echocardiography have some
strengths and weaknesses that need to be addressed. Until now,
conventional echocardiography has been the most commonly
used noninvasive imaging modality to quantify cardiac function
[22]; therefore, most studies of cancer patients and survivors
are based on LVEF. Impaired LVEF is a late sign of cardiac
damage, and the chance of recovery is already small. Speckle
tracking echocardiography might overcome this limitation as
it has been shown to be superior to LVEF in diagnosing cardiac
dysfunction and predicting cardiac mortality in patients with
underlying cardiac disease [34,35] and in adults undergoing
cancer therapy [36]. Also, there are studies that have investigated
the evidence of strain measurements for the surveillance of
chemotherapy-related cardiac dysfunction in adult cancer
patients (SUCCOUR trial) [37]. However, for CCS, we do not
know the prognostic value of speckle tracking echocardiography
yet. Another limitation is that strain analysis depends on image
quality, and is age-, sex-, vendor-, and software-dependent [38].
We try to overcome this by strictly adhering to our standard
operating procedures and using reference values stratified by
age and sex using the same vendor (GE Vivid E9) and software
(Tomtec Imaging Systems) [24]. By using only one type of
vendor equipment and software, we also avoid intervendor
variability.
First among this study's limitations is that it is currently confined
to a single center. However, the 9 centers treating children and
adolescents with cancer in Switzerland collaborate closely and
use uniform treatment protocols; we therefore expect that results
from the University Hospital Bern are representative of all 9
centers in the country. We are also concerned that our study
includes a heterogeneous group of CCS with relatively small
numbers of patients in each subgroup defined by treatment
exposure or type of cancer. We plan to overcome this limitation
by expanding this study to a nationwide study that includes all
9 Swiss Pediatric Oncology Group clinics. Also, our study might
be affected by survival bias, as the most severely affected
childhood cancer patients and survivors have already died. This
could underestimate the cardiotoxic effect of anticancer
management. We will collect the number of cardiac deaths from
the Swiss Mortality Statistics, and this information will be
considered in the analysis and interpretation of the results.
Among this study's several strengths is our attempt to include
the complete cohort of survivors treated at the University
Children’s Hospital Bern since 1976 based on the database of
the Childhood Cancer Registry. We repeat our invitation to
nonresponders several times and ask about reasons for not
participating. This reduces the potential for selection bias. Also,
we link the Childhood Cancer Registry with the Swiss Federal
Statistical Office to collect cardiac causes of death in ≥5-year
survivors. Second, we have access to all treatment exposures
based on actual chemotherapy road maps and are able to look
into dose-response relationships. Third, we will continuously
include new 5-year survivors and therefore gain knowledge
about the risk of cardiac dysfunction in younger patients treated
more recently. Finally, our study has been set up within routine
survivorship follow-up care using the experience of a
multidisciplinary and interdisciplinary team with close
collaboration between pediatric and adult cardiology, pediatric
hematology and oncology, and clinical epidemiology.
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The preliminary results from this retrospective, single-center
study suggest that a standardized cardiac assessment that is part
of routine follow-up care done in collaboration between pediatric
and adult specialists is feasible in Switzerland and widely
accepted by survivors and health care providers. In the next
step, we will include more Swiss centers in the study to provide
standardized clinical follow-up care longitudinally to all CCS
on a nationwide scale.
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2D: 2-dimensional
3D: 3-dimensional
A: late diastolic left ventricular filling velocity
CCS: childhood cancer survivors
E: early diastolic left ventricular filling velocity
E/A: early to late left ventricle filling velocity
E’: mitral annular early diastolic velocity
E/e’: peak mitral flow velocity
GCS: global circumferential strain
GLS: global longitudinal strain
GRS: global radial strain
ICCC3: International Classification of Childhood Cancer third edition
LA: left atrial
LV: left ventricular
LVEF: left ventricular ejection fraction
RA: right atrium
RV: right ventricle
STS: 1-minute sit-to-stand test
TR: tricuspid regurgitation
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